“Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression”
Study TRD subjects' resistance to at least 2 different antidepressants, we hypothesize that because of their significant depression and treatment resistant status they are most likely to exhibit BSMN pathway abnormalities.
Drug - Monoamine Oxidase Inhibitor (MAOI)
Monoamine Oxidase Inhibitor
Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression
NCT03109717
mbk0Ed